Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on
Go back to Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on| (NASDAQ: ROIV) | Delayed: 40.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.82 | 52 Week High | $ | |||
| Open | $40.82 | 52 Week Low | $ | |||
| Day High | $40.82 | P/E | N/A | |||
| Day Low | $40.82 | EPS | $ | |||
| Volume | 160,682 | |||||
